Erbitux® (
cetuximab) is a drug prescribed for the treatment of cancer. Specifically, it is approved for
squamous cell carcinoma of the head and neck and certain kinds of advanced
colorectal cancer. The average length of treatment for Erbitux will depend on the condition being treated and how well you tolerate the drug.
For example, if you are receiving Erbitux in addition to radiation treatment for head and neck cancer, you will be given your first dose one week before starting radiation. Subsequent doses will be given so that the dose is complete one hour before radiation. Treatment will continue for the remainder of radiation therapy (normally six or seven weeks).
(Click Erbitux Dosage to learn more about how long treatment can last, the factors that will affect your dose, and how to ensure the drug's safety and effectiveness.)
HealthSavvy Sign In
|